NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today the start of a Phase 2a proof-of-concept study of its lead Aganocide(R) compound NVC-422 in impetigo.
NovaBay's partner in the impetigo trial is Galderma, S.A. the world's leading dermatology company. NovaBay also is currently engaged in clinical studies of NVC-422 for viral conjunctivitis with its other major partner Alcon (NYSE: ACL), the world's leading eye care company.
This double blind, randomized, sequential group study will evaluate the safety and efficacy of a dermal formulation of NVC-422 in 120 patients ages 2 to 12 at two experienced clinical centers in the Dominican Republic. Over 15 patients have been enrolled so far and final results are expected in the first half of 2010.
Impetigo is one of the most common bacterial skin infections affecting over one million people in the US alone, primarily infants and children between the ages of two and six.(1) Impetigo usually starts with direct bacterial invasion of healthy skin or when bacteria enter a break in the skin, such as a cut, scratch or insect bite. Symptoms begin with red or pimple-like sores surrounded by red skin. These sores usually occur on the face, arms and legs and fill with pus, then break open after a few days and form a thick crust. Impetigo can spread by contact with sores or nasal discharge from an infected person.(2)